Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.
Cognitive behavioral therapy for insomnia (CBT-I) is a type of therapy developed to improve sleep and sleep-related anxiety. Researchers have found that CBT-I can be an effective treatment option ...
Laing recommends beans, as well as other legumes like lentils, as a source of energy-boosting protein. Beans are also high in fiber, and boast a number of other health benefits. Black beans in ...
It has been held back by the extremely low cost of established, generic insomnia drugs, which have dragged down the overall value of the market for medicines to aid sleep. Belsomra’s modest ...
It’s approved for use to treat depression but is also often prescribed for several other conditions like pain, migraines, and insomnia ... including medications that can help.
Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis (MASH) therapies. BioWorld Asia Deals ...